Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/1999
11/30/1999CA1340834C Derivatives of human/bovine basic fibroblast growth factor
11/25/1999WO1999060171A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
11/25/1999WO1999060125A2 Secreted proteins
11/25/1999WO1999060020A1 Secreted proteins and polynucleotides encoding them
11/25/1999WO1999059997A1 Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
11/25/1999WO1999059994A1 Retroviral protease inhibiting compounds
11/25/1999WO1999059992A1 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
11/25/1999WO1999059989A1 Process for the preparation of a benzo fused heterocyclo sulfonyl halide intermediate
11/25/1999WO1999059986A1 Fumagillol derivatives and processes for preparing the same
11/25/1999WO1999059975A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999WO1999059974A1 Tetraisoquinololine derivatives as modulators of dopamine d3 receptors
11/25/1999WO1999059973A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999WO1999059972A1 Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists
11/25/1999WO1999059964A1 Novel analogs of 16-hydroxyeicosatetraenoic acid
11/25/1999WO1999059960A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999WO1999059959A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999WO1999059957A1 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
11/25/1999WO1999059635A1 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
11/25/1999WO1999059632A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
11/25/1999WO1999059629A1 Humanized antibodies that recognize verotoxin ii and cell line producing same
11/25/1999WO1999059628A2 Combination therapy for the treatment of tumors
11/25/1999WO1999059620A1 Angiostatin receptor
11/25/1999WO1999059617A2 Immunoregulator
11/25/1999WO1999059615A1 Hybrid polypeptides with enhanced pharmacokinetic properties
11/25/1999WO1999059612A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999WO1999059609A2 Use of hmg proteins for the preparation of medicaments having cytotoxic activity
11/25/1999WO1999059608A2 Osteoporosis treatment
11/25/1999WO1999059606A1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process
11/25/1999WO1999059602A1 Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
11/25/1999WO1999059597A1 Ionophore containing composition for modulating amyloidosis
11/25/1999WO1999059596A1 Glucocorticoid receptor antagonists for the treatment of dementia
11/25/1999WO1999059594A1 Potassium channel agonists
11/25/1999WO1999059591A1 Pyrazinone thrombin inhibitors
11/25/1999WO1999059578A1 Triterpene compositions and methods for use thereof
11/25/1999WO1999059571A1 Use of amyloid inhibitors for modulating neuronal cell death
11/25/1999WO1999059563A2 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
11/25/1999WO1999059557A1 Multiparticulate pharmaceutical form with programmed and timed release and preparation method
11/25/1999WO1999059553A1 Effervescent preparations
11/25/1999WO1999059526A2 Protease inhibitors
11/25/1999WO1999059524A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation
11/25/1999WO1999059499A2 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
11/25/1999WO1999050249A3 Pyrimidines and triazines as integrin antagonists
11/25/1999WO1999048523A3 Antagonists of the inflammatory mediator oncostatin m (osm)
11/25/1999WO1999048507A3 Steroidal saponins for treating alzheimer's disease
11/25/1999WO1999048484A3 Use of cabergoline in the treatment of restless legs syndrome
11/25/1999WO1999047545A3 Inhibitors of caspases
11/25/1999WO1999047517A8 Novel heterocyclic compounds
11/25/1999WO1999047158A3 Therapeutic chemokine receptor antagonists
11/25/1999WO1999043832A3 Human proteinase molecules
11/25/1999WO1999043787A3 A living chimeric skin replacement
11/25/1999WO1999042602A3 Fermentative preparation process for cytostatics and crystal forms thereof
11/25/1999WO1999040068A3 2-aminoquinoline derivatives having d4-agonistic activity
11/25/1999WO1999040067A3 Benzisoxazole derivatives having d4-antagonistic activity
11/25/1999WO1999038976A3 Human growth factor homologs
11/25/1999WO1998041226A9 Pharmaceutical combined preparations containing erythropoietin and iron preparations
11/25/1999CA2333203A1 Methods for modulating neuronal cell death
11/25/1999CA2332774A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999CA2332771A1 Ionophore containing composition for modulating amyloidosis
11/25/1999CA2332711A1 Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of neurogenic inflammation
11/25/1999CA2332531A1 Protease inhibitors
11/25/1999CA2332507A1 Angiostatin receptor
11/25/1999CA2332505A1 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
11/25/1999CA2332338A1 Hybrid polypeptides with enhanced pharmacokinetic properties
11/25/1999CA2332316A1 Tetraisoquinololine derivatives as modulators of dopamine d3 receptors
11/25/1999CA2332279A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999CA2332272A1 Novel analogs of 16-hydroxyeicosatetraenoic acid
11/25/1999CA2332239A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999CA2331756A1 Retroviral protease inhibiting compounds
11/25/1999CA2329916A1 Potassium channel agonists
11/25/1999CA2329914A1 Pyrazinone thrombin inhibitors
11/25/1999CA2329868A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
11/25/1999CA2328699A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999CA2328529A1 Immunoregulator from a human chorionic gonadotropin preparation
11/25/1999CA2328527A1 Secreted proteins
11/25/1999CA2328509A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
11/25/1999CA2328489A1 Secreted proteins and polynucleotides encoding them
11/25/1999CA2327585A1 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
11/25/1999CA2327299A1 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
11/24/1999EP0958824A2 Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
11/24/1999EP0958374A1 T1 receptor-like ligand i
11/24/1999EP0958354A1 Thiomethylene group-containing aldehyde cysteine and serine protease inhibitors
11/24/1999EP0958293A1 Nanomolar, non-peptide inhibitors of cathepsin d
11/24/1999EP0958290A1 1,4-dihydropyridin derivatives and their use in therapy
11/24/1999EP0958287A1 Sulfamide-metalloprotease inhibitors
11/24/1999EP0958282A1 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
11/24/1999EP0958275A1 Selective inhibitors of prostaglandin endoperoxide synthase-2
11/24/1999EP0957932A2 A method and composition for enabling passage through the blood-brain barrier
11/24/1999EP0957929A1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
11/24/1999EP0957926A1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein
11/24/1999EP0957924A1 Certain phosphinyl derivatives useful as naaladase inhibitors
11/24/1999EP0957918A1 Method of treating or inhibiting neutropenia
11/24/1999EP0957917A1 Vitronectin receptor antagonists
11/24/1999EP0957914A1 Formulation of 5-ht agonists
11/24/1999EP0957913A1 N-linked sulfonamides of heterocyclic thioesters
11/24/1999EP0957911A1 HESPERIDIN AND HESPERETIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR
11/24/1999EP0957908A1 Fibrinogen receptor antagonists
11/24/1999EP0957907A1 Il-8 receptor antagonists
11/24/1999EP0845045A4 Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
11/24/1999EP0808165A4 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/24/1999EP0797663A4 Sox-9 gene and protein and use in the regeneration of bone or cartilage
1 ... 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 ... 1564